(1S,2R)-2-phenylcyclopropanecarboxamide | 1009-39-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1S,2R)-2-phenylcyclopropanecarboxamide
• 英文别名: cis-2-Phenyl-cyclopropan-carbonsaeure-amid；rel-(1R,2S)-2-Phenylcyclopropanecarboxamide；(1S,2R)-2-phenylcyclopropane-1-carboxamide
• CAS: 1009-39-8
• 化学式: C₁₀H₁₁NO
• 分子量: 161.203
• InChiKey: IOWKRFFHXWDUIS-IUCAKERBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (1S,2R)-2-phenylcyclopropanecarboxamide 、 氢化铝锂 以86%的产率得到
  参考文献：
  名称：

  BORNE R. F.; FORRESTER M. L.; WATERS I. W., J. MED. CHEM. , 1977, 20, NO 6, 771-776

  摘要：

  DOI：
• 作为产物：
  描述：

  (1S,2R)-2-phenylcyclopropanecarboxylic acid 、 羟胺 、 氯化亚砜 生成 (1S,2R)-2-phenylcyclopropanecarboxamide
  参考文献：
  名称：

  BORNE R. F.; FORRESTER M. L.; WATERS I. W., J. MED. CHEM. , 1977, 20, NO 6, 771-776

  摘要：

  DOI：

文献信息

• [EN] PIPERIDINE CXCR7 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR DE CXCR7 PIPÉRIDINE
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2018019929A1

  公开（公告）日：2018-02-01

  The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2, and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

  本发明涉及式(I)的哌啶衍生物，其中Ar1、Ar2、RAr1、R1、R2和R3如描述中所述，它们的制备，其药学上可接受的盐，以及它们作为药物的用途，含有一个或多个式(I)化合物的药物组合物，特别是它们作为CXCR7受体调节剂的用途。
• A novel approach to enantiopure cyclopropane compounds from biotransformation of nitrilesElectronic supplementary information (ESI) available: preparation of racemic nitrile, amides and acids; spectroscopic data of racemic nitriles; biotransformation of racemic amides; chiral HPLC analyses of nitriles, amides, acids and amines. See http://www.rsc.org/suppdata/nj/b2/b200110a/
  作者：Mei-Xiang Wang、Guo-Qiang Feng

  DOI：10.1039/b200110a

  日期：2002.10.30

  Rhodococcus sp. AJ270, a powerful and versatile nitrile hydratase/amidase containing microbial whole-cell system, catalyzed the enantioselective hydrolysis of both racemic trans- and cis-2-arylcyclopropanecarbonitriles to afford the corresponding amides and acids with enantiomeric excesses as high as >99%. The reaction rate and enantioselectivity observed for both nitrile hydratase and amidase were also strongly dependent upon the nature of the substituent and substitution pattern on the benzene ring of the substrates. The application of and the advantages of biotransformation of nitriles were demonstrated by preparing (1S,2R)-2-phenylcyclopropylamine and (1R,2R)-2-phenylcyclopropylmethylamine through facile and straightforward chemical manipulations of (1S,2S)-2-phenylcyclopropanecarboxylic acid and (1R,2R)-2-phenylcyclopropanecarboxamide, respectively.

  Rhodococcus sp. AJ270 是一种功能强大、用途广泛的腈水解酶/酰胺酶，含有微生物全细胞系统，可催化外消旋反式和顺式-2-芳基环丙烷甲腈的对映选择性水解，生成相应的酰胺和酸，对映过量高达 99%以上。腈水解酶和酰胺酶的反应速率和对映体选择性还与底物苯环上取代基的性质和取代模式密切相关。通过对(1S,2S)-2-苯基环丙烷羧酸和(1R,2R)-2-苯基环丙烷甲酰胺进行简单直接的化学处理，分别制备出(1S,2R)-2-苯基环丙胺和(1R,2R)-2-苯基环丙基甲胺，证明了腈类生物转化的应用和优势。
• Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
  申请人：Holder Swen

  公开号：US20050026918A1

  公开（公告）日：2005-02-03

  The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C 1 -C 10 -alkyl, aryl, aryl-(C 1 -C 10 -alkyl)-, heteroaryl, heteroaryl-(C 1 -C 10 -alkyl)-, heterocyclyl, heterocyclyl-(C 1 -C 10 -alkyl)-, C 3 -C 10 -cycloalkyl, polycycloalkyl, C 2 -C 10 -alkenyl or C 2 -C 10 -alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.

  本发明涉及一种新型吡啶并咪唑酮衍生物，其通式为(I)，其中A为A1或A2；R为未取代或至少单取代的C1-C10烷基、芳基、芳基-(C1-C10烷基)-、杂芳基、杂芳基-(C1-C10烷基)-、杂环基、杂环基-(C1-C10烷基)-、C3-C10环烷基、多环环烷基、C2-C10烯基或C2-C10炔基，Ar为未取代或至少单取代的芳基或杂芳基。
• COMPLEMENT PATHWAY MODULATORS AND USES THEREOF
  申请人：Altmann Eva

  公开号：US20150141455A1

  公开（公告）日：2015-05-21

  The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了化合物I的公式：（I），本发明的化合物制备方法及其治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。
• Piperdine CXCR7 receptor modulators
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：US10752620B2

  公开（公告）日：2020-08-25

  The present invention relates to piperidine derivatives of formula (I) wherein Ar1, Ar2, RAr1, R1, R2 and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

  本发明涉及式 (I) 的哌啶衍生物 其中 Ar1、Ar2、RAr1、R1、R2 和 R3 如描述中所述，它们的制备，它们的药学上可接受的盐，以及它们作为药物的用途，含有一种或多种式 (I) 化合物的药物组合物，特别是它们作为 CXCR7 受体调节剂的用途。